Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: Analysis of results from 3 randomized phase 3 clinical trials

JAMA Dermatology

Volumn 152, Issue 6, 2016, Pages 661-669

  Armstrong, April W ^a   Lynde, Charles W ^b   McBride, Sandy R ^c   Ståhle, Mona ^d   Edson Heredia, Emily ^e   Zhu, Baojin ^e   Amato, David ^e   Nikaï, Enkeleida ^f   Yang, Fan Emily ^e   Gordon, Kenneth B ^g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e ELI LILLY AND COMPANY   (United States)

^f Eli Lilly Benelux   (Belgium)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; IXEKIZUMAB; PLACEBO; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ABSENTEEISM; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRESENTEEISM; PRIORITY JOURNAL; PRODUCTIVITY; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT PSORIASIS; CLINICAL TRIAL; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TREATMENT OUTCOME;

ABSENTEEISM; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE III AS TOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; EFFICIENCY; ETANERCEPT; FEMALE; HUMANS; MALE; MIDDLE AGED; PRESENTEEISM; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84975132508     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2016.0269     Document Type: Article

References (42)

1. Edson-Heredia E, Zhu B, Lefevre C, et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venereol. 2015;29(5):955-963.
2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.
3. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321-328.
4. Wu JJ, Choi YM, Bebchuk JD. Risk of myocardial infarction in psoriasis patients: a retrospective cohort study. J Dermatolog Treat. 2015;26(3):230-234.
5. Wu JJ, Nguyen TU, Poon KY, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67(5):924-930.
6. Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. Dermatology. 2012;225(2):121-126.
7. Fried RG, Friedman S, Paradis C, et al. Trivial or terrible? the psychosocial impact of psoriasis. Int J Dermatol. 1995;34(2):101-105.
8. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383-392.
9. Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199-205.
10. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3, pt 1):401-407.
11. Sampogna F, Tabolli S, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. 2012;92(3):299-303.
12. Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges. 2007;5(7):566-574.
13. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385.
14. Allen H, Bunn WB III, Naim AB. The self-reported health and productivity burden of autoimmune disorders at a major self-insured employer. J Occup Environ Med. 2012;54(9):1049-1063.
15. Augustin M, Glaeske G, Schäfer I, Rustenbach SJ, Hoer A, Radtke MA. Processes of psoriasis health care in Germany - long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges. 2012;10(9):648-655.
16. Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005;3(7):511-518.
17. Carrascosa JM, Pujol R, Daudén E, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol. 2006;20(7):840-845.
18. Chan B, Hales B, Shear N, et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg. 2009;13(4):192-197.
19. Langenbruch AK, Radtke MA, Augustin M. Quality of psoriasis care from the patients' perspective - results of the national health care study PsoReal. Eur J Dermatol. 2012;22(4):518-524.
20. Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24(9):1075-1082.
21. Schöffski O, Augustin M, Prinz J, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges. 2007;5(3):209-218.
22. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2012;7(12):e52935.
23. Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17(1):24-28.
24. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772-780.
25. Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51(12):1432-1440.
26. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213(2):102-110.
27. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-365.
28. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62(4):929-939.
29. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-1199.
30. Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33(1):13-23.
31. Griffiths CE, Reich K, Lebwohl M, et al; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551.
32. Gordon K, Blauvelt A, Langley R, et al. Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 60-week results from a double-blind phase 3 induction and randomized withdrawal study (UNCOVER-1). Abstract presented at: American Academy of Dermatology 73rd Annual Meeting; March 20-24, 2015; San Francisco, CA. https://www.aad.org/Symposium/LBAM2015/file/index/Late-breaking%20Research%20Abstract%20Book.pdf. Accessed August 5, 2015.
33. WPAI. SHP V2.0. Reilly Associates. Updated August 18, 2010. http://www.reillyassociates.net/WPAI-SHP.html. Accessed August 28, 2015.
34. Mattila K, Leino M, Mustonen A, Koulu L, Tuominen R. Influence of psoriasis on work. Eur J Dermatol. 2013;23(2):208-211.
35. Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases - focusing on work productivity and disability. J Rheumatol Suppl. 2011;88:55-61.
36. Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651-658.
37. Bureau of Labor Statistics. May 2014 National Occupational Employment and Wage Estimates - United States. US Department of Labor website. http://www.bls.gov/oes/current/oes-nat.htm. Accessed June 24, 2015.
38. Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;66(2):e67-e76.
39. Papp KA, Signorovitch J, Ramakrishnan K, et al. Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials. Clin Drug Investig. 2011;31(1):51-60.
40. Reich K, Schenkel B, Zhao N, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat. 2011;22(6):337-347.
41. Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a ehase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18(6):341-350.
42. Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M. Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. Appl Health Econ Health Policy. 2012;10(5):343-353.